Arestat™ stabilization technologies are inspired by Arecor’s insight into the ways in which proteins, biologics and complex structures (viruses, vectors, macromolecules) degrade during storage or stressed conditions whether in solution or a dry state. There are a number of physical and chemical pathways by which they degrade. Arecor has developed a set of formulations ‘tools’ to address the principal pathways of degradation which lead to the loss of structural integrity and biological activity. For example, some ionic species commonly included in pharmaceutical formulations can contribute to the instability of biopharmaceuticals during long term storage. These species can instigate irreversible changes causing a plethora of problems such as loss of activity, the formation of aggregates and even the appearance of unwanted immunogenicity.

Arecor have created and patented new approaches of controlling the ionic environment of biologicals in pharmaceutical and diagnostic applications, in order to improve their stability profiles in solution or dry state. These approaches collectively form the proprietary stabilization technologies designated Arestat™. Arestat™ comprises two fundamentally different aspects of the protein stabilization technologies. Both utilize FDA and EMEA approved buffers and excipients in an unconventional manner to achieve the desired stability. One aspect, Arestat-T™ is concerned with the stabilization of biologicals at nominal or very high concentrations during storage at refrigerated, ambient or elevated temperatures. The second aspect, Arestat-R™, is concerned with the stabilization of biologicals exposed to ionizing radiation (e.g. gamma radiation).

Arestat-T™ and Arestat-R™ can be applied singly or in combination to improve significantly the stability of recombinant proteins, vaccines and macromolecules.